Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
  • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to stable formulations and lyophilizates comprising a high content of the disodium salt of 5,10-methylene-(6R)-tetrahydrofolic acid (5,10-CH2-(6R)- THF*Na2), sulfate and citrate.
• 5,10-methylenetetrahydrofolic acid is known as a medicament used in combination with 5- fluorouracil (5-FU) in the treatment of solid tumors (Seley, K. L. Drugs 4 (1), 99, 2001).
• the active isomeric form 5,10-methylene-(6R)-tetrahydrofolic acid (referred to as 5,10-CH2-(6R)- THF in the following), achieves its chemotherapeutic effect together with the base analogue and 5-FU metabolite 5-FdUMP by inhibiting the enzyme thymidylate synthase (TS).
• TS catalyzes the conversion of deoxyuridylate (dUMP) to deoxythymidylate (dTMP), which is an essential building block for DNA synthesis.
• Deactivation of TS occurs by formation of a covalent, ternary inhibition complex between TS, the base analogue 5-FdUMP, which is a metabolite of 5-FU, and 5,10-CH 2 -(6
• An enhancement of the cytotoxic effect of 5-FU can be achieved by increasing the intracellular concentration of 5,10-CH2-(6R)-THF, whereupon the stability of the ternary inhibition complex is increased. This causes direct inhibition of DNA synthesis and repair, which ultimately results in cell death and delay of tumor growth.
• the application of respective stable, high content products is desired.
• 5,10-CH2-(6R)-THF is highly susceptible to oxidation and chemical degradation that results in unfavorably high impurity levels.
• Susceptibility to oxidation and chemical degradation of 5,10-CH2-(6R)-THF is especially high in aqueous solution, or when the compound is present in its amorphous form where it has a large surface (e.g. in its pharmaceutical use form as a lyophilizate), or in re-dissolved form such as solutions for injection.
• the respective composition needs to fulfill several requirements including high chemical and isomeric stability, such that effective storage over an acceptable period of time can be achieved, without exhibiting a significant change in the composition's physicochemical characteristics, ease of handling and processing, etc.
• 5,10-methylenetetrahydrofolic acid is an addition product of tetrahydrofolic acid and formaldehyde (see e.g. Poe, M. et al. Biochemistry 18 (24), 5527, 1979; Kallen, R. G. Methods in Enzymology 18B, 705, 1971) and is known for its extremely high sensitivity to oxidation by air as well as instability in neutral and/or acidic environments, potentially leading to chemical degradation and/or hydrolysis (see e.g. Odin, E. et al., Cancer Investigation 16 (7), 447, 1998; Osborn, M. J. et al., J. Am. Chem. Soc. 82, 4921, 1960; Hawkes, J., and Villota, R. Food Sci. Nutr. 28, 439, 1989).
• compositions of 5,10-methylenetetrahydrofolates have included e.g. (i) rigorous exclusion of atmospheric oxygen by the use of special technical devices for the reconstitution of solid formulations and the injection of 5,10-methylenetetrahydrofolates in an air-free environment (see e.g. Odin, E. et al., Cancer Investigation 16 (7), 447, 1998; U.S. Pat. No. 4,564,054); (ii) addition of a reducing agent such as L(+)-ascorbic acid or salts thereof, reduced gamma-glutathione, beto-mercaptoethanol, thioglycerol, N-acetyl-L-cysteine, etc. as an antioxidant for the highly sensitive 5,10-methylenetetrahydrofolic acid and for tetrahydrofolic acid in particular.
• a reducing agent such as L(+)-ascorbic acid or salts thereof, reduced gamma-glutathione,
• Nonformulated 5,10-methylene- (6R,S)-tetrahydrofolic acid was thus found to loose 2.2% purity per hour, resulting in a purity of 84% after 7 hours, whereas formulations containing 250 % w/w trisodium citrate was found to loose 1.4 % purity per hour, resulting in a purity of 89% after 7 hours.
• Formulations containing both 250 % w/w trisodium citrate and 175 % w/w ascorbic acid had much higher stability, loosing only 0.5% purity per hour, resulting in a purity of about 96% after 7 hours.
• Lyophilizates of 5,10-CH2-(6R)-THF containing dicarboxylic acids and/or tricarboxylic acids such as citric acid and/or other stabilizers have also been disclosed in e.g. WO 2019/034673, US 2007/0099866 and US10059710 B2. Solutions disclosed therein for the purpose of preparing lyophilizates contain at most 2-3% by weight 5,10-CH2-(6R)-THF.
• compositions which comprise the disodium salt of 5,10-CH2-(6R)-methylene tetrahydrofolic acid (denoted hereinafter 5,10-CH2- (6R)-THF*Na2) in combination with citrate and an alkali metal sulfate have comparable or even higher stability than compositions comprising 5,10-methylenetetrahydrofolic acid, citrate and reducing agents such as L-(+)-ascorbic acid.
• solutions of 5,10-CH2-(6R)-THF*Na2, alkali metal sulfate and citrate remain highly stable for hours, which solutions according to the present invention are next converted into lyophilizates with a similar good stability.
• lyophilizates comprise 5,10-CH2-(6R)-THF*Na2, alkali metal sulfate and citrate and no other stabilizing agents, and thus overcome the previously discussed known drawbacks, and allow for the preparation of solid-state pharmaceutical compositions of high purity and a low content of either oxidation products or other chemical degradation products.
• the present invention thus relates to a lyophilized composition which comprises the disodium salt of 5,10-methylene-(6R)-tetrahydrofolic acid (5,10-CH2-(6R)- THF*Na2), citrate and an alkali metal sulfate.
• a second aspect of the present invention is directed to a process for the preparation of the lyophilized composition according to the first aspect, which process comprises the following steps: i. dissolving (6S)-tetrahydrofolic acid in water with NaOH, ii. adjusting the pH of the solution to 8.6 ⁇ 0.5 ill. adding 110-120 mol% formaldehyde, iv. stirring the reaction mixture until reaction has completed, v. adding from about 40 - 200 mol-% of an alkali metal sulfate, and from about 200 - 400 mol-% of citrate, vi. filtering the reaction mixture to obtain a clear solution, and vii. freeze-drying the obtained clear solution, which process does not comprise adding any further reducing agents or antioxidants.
• the present invention further relates to a lyophilized composition according to the first aspect for use in the treatment of cancer, or in cancer therapy, in a human patient.
• the present invention further relates to a method of treatment of cancer, or of cancer therapy, in human patients comprising administering a lyophilized composition according to the first aspect to a human patient in need thereof.
• the present invention further relates to the use of a lyophilized composition according to the first aspect for the manufacture of a medicament for the treatment of cancer in human patients.
• Figure 1 is a table adapted from WO 2007/064968 which demonstrates the stability over time of non-formulated and various formulated forms of 55,10-methylene-(6R,S)-tetrahydrofolic acid (% normalized purity).
• Nonformulated 5,10-methylene-(6R,S)-tetrahydrofolic acid was found to loose 2.2% purity per hour, resulting in a normalized purity of 45% after 24 hours.
• a reference formulation containing 250 % w/w trisodium citrate was found to loose 1.4% purity per hour, resulting in a normalized purity of 65% after 24 hours.
• Formulations #1 and #2 containing both 250 % w/w trisodium citrate and 175 % w/w ascorbic acid had a much higher stability, loosing only 0.5% purity per hour, resulting in a normalized purity of about 90% after 24 hours.
• Figure 2 is adapted from Figure 1 in WO 2007/064968 and demonstrates graphically the tabulated results of Fig. 1 herein.
• Figure 3 is a table adapted from Example 1 of WO 2007/064968 showing the composition of the non-formulated and formulated forms of 5,10-methylene-(6R,S)-tetrahydrofolic acid shown in Fig. 1 and Fig. 2 herein. As can be seen, the most stable compositions (formulations #1 and #2) contain less than 20% of the active ingredients, 10-methylene-(6R,S)- tetrahydrofolic acid.
• Figure 4 shows the purity analyses of three solutions comprising 75 mg/mL of the disodium salt of 5,10-methylene-(6R)-tetrahydrofolic acid, citrate and sodium sulfate tested at three different conditions: 25 °C, 5 °C and 5 °C with lmg/mL sodium ascorbate added as antioxidant. The results are shown for a total period of 7 hours. As can be seen from the graphs, the solutions are very stable under the storage conditions. At 5 °C there is practically no change in purity, which remains at about 97% (area%). As can also be seen, the effect of ascorbate is minimal. At 25 °C, the purity over 7 hours changes from an initial purity of about 96% to a purity of about 95.5% (area%).
• Figure 5 shows analyses of the same three solutions of sodium salt of 5,10-methylene-(6R)- tetrahydrofolic acid as shown in Figure 4 herein.
• Figure 5 the development over 7 hours of the main impurity, 10-formyl-(6R)-tetrahydrofolic acid (10-FTHFA) in the solutions is shown.
• 10-FTHFA 10-formyl-(6R)-tetrahydrofolic acid
• Figure 6 shows the stability of a lyophilized composition comprising disodium 5,10- methylene-(6R)-tetrahydrofolate, citrate and sodium sulfate at at 5 °C, 25°C, and 40 °C.
• the lyophilized compositions are very stable under the storage conditions. Even at room temperature there is practically no change in purity when stored for 24 months (99.8% relative purity %w/w).
• Figure 7 shows the development of the main impurity, 10-formyl-(6R)-tetrahydrofolic acid (10-FTHFA), in a lyophilized composition comprising disodium 5,10-methylene-(6R)- tetrahydrofolate, citrate and sodium sulfate when stored at at 5 °C, 25°C, and 40 °C.
• the level of this impurity is practically constant over time.
• stabilizers or “stabilizing agents” relates to buffers such as citrate (or citric acid and salts thereof); dicarboxylates such as succinate, malate and maleate; tris(hydroxymethyl)aminomethane (TRIS); N-tris(hydroxymethyl)methyl-2-aminoethane- sulfonic acid (TES); 3-(N-morpholino)propanesulfonic acid (MOPS); N,N-bis(2-hydroxyethyl)- 2-aminoethanesulfonic acid (BES); MES; MOPSO; HEPES; phosphate; carbonate; ammonium; mono-, di-, and tri-alkylammonium; mono-, di-, and tri-hydroxylalkylammonium; glutamate; borate; lactate, as well as combinations of these.
• buffers such as citrate (or citric acid and salts thereof); dicarboxylates such as succinate, malate and maleate; tris(hydroxymethyl)aminomethan
• stabilizers or “stabilizing agents” further relates to reducing agents such as L-(+)ascorbic acid or salts thereof, reduced y- glutathione, p-mercaptoethanol, thioglycerol, N-acetyl-L-cysteine, etc. which may act as an antioxidant for the sensitive 5,10-methylenetetrahydrofolic acid, and for the tetrahydrofolic acid in particular.
• buffer relates to citrate (or citric acid and salts thereof), dicarboxylates such as succinate, malate and maleate, tris(hydroxymethyl)aminomethane (TRIS); N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); 3-(N- morpholino)propanesulfonic acid (MOPS); N,N-bis(2-hydroxyethyl)-2-aminoethane-sulfonic acid (BES); MES; MOPSO; HEPES; phosphate; carbonate; ammonium ; mono-, di-, and trialkylammonium; mono-, di-, and tri-hydroxylalkylammonium; glutamate; borate; lactate, as well as combinations of these.
• TAS tris(hydroxymethyl)aminomethane
• TES N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid
• MOPS 3-(N- morpholino)propanesul
• reducing agent or "antioxidants” relates to L-(+)ascorbic acid or salts thereof, reduced y-glutathione, p-mercaptoethanol, thioglycerol, and N-acetyl-L- cysteine.
• solvent relates to solvents which may be used in freeze drying processes.
• “Solutions” as referred to in the present text comprise aqueous solutions as well as solutions in organic solvents.
• aqueous solutions mean solutions in water, saline solutions, water containing small amounts of buffers, water containing isotonic amounts of NaCI, or mixtures of water with organic solvents, and the like.
• Typical organic solvents include DMSO, acetonitrile, acetone, methanol, or ethanol.
• composition comprising 5,10-CH2-(6R)-THF*Na2
• composition comprising 5,10-CH2-(6R)-THF*Na2
• compositions such as lyophilizates, including lyophilizates which have been reconstituted, eg. for use in medical treatment.
• aqueous solutions comprising the disodium salt of 5,10-methylene-(6R)-tetrahydrofolic acid (denoted hereinafter 5,10-CH2-(6R)-THF*Na2) in combination with citrate and an alkali metal sulfate have comparable or even higher stability than aqueous solutions comprising 5,10-methylenetetrahydrofolic acid, citrate and reducing agents such as L-(+)-ascorbic acid, which solutions according to the present invention are next converted into lyophilizates with a similar good stability.
• Alkali metal sulfates are not reducing agents per se and are therefore normally considered chemically inert. The found stability is therefore surprising.
• Lyophilizates of the present invention contain more than 20 % w/w 5,10-CH2-(6R)-THF*Na2 such as more than 25% w/w, such as more than 30% w/w, such as more than 35% w/w, or such as about 40 % w/w 5,10-CH2-(6R)-THF*Na 2 .
• the lyophilized powders have even higher stability than the aqueous solutions and can be reconstituted with a diluent to a set concentration for administration. Such reconstituted lyophilizates can be administered either intramuscularly or intravenously.
• Bulking agents such as mannitol may be added to the solutions before the freeze-drying process to promote an acceptable lyophilized cake formation.
• the structure and porosity of the lyophilized cake is important, since good pore formation may facilitate drying and transport of the water during the drying cycle.
• electrolytes, sugars and/or polyols such as dextrose, glycerol, mannitol and sodium chloride may be added to adjust the osmolality. Osmolality adjustment can be done before or after freeze drying.
• the reconstituted lyophilisate solution preferably has an osmolality in the range of 250- 350 mOsm. However, an osmolality of 200 - 600 mOsm can be tolerated as well, and will depend on the volume to be administered as well as the injection/infusion time.
• the pH of the solutions is typically in the range of 8.0 to 9.0, preferably in the range of 8.4 to
• Stability is a critical property and component of pharmaceutical formulation studies and drug development. Stability studies are performed both in solution and solid state. It is an established fact that the solution state and solid-state stability can differ both qualitatively and quantitatively. Extensive studies were performed for stability of the drug substance and pharmaceutical compositions thereof by exposing it to variety of stressors, like high temperature and/or high humidity. These studies also provide information on the degradation products and help in developing meaningful specifications as well as the intrinsic stability of the pharmaceutical composition. Most common pathways for drug degradation include i.a. hydrolysis, oxidation, and photochemical degradation.
• the purpose of stability testing is to provide evidence on how the quality of a product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to establish a suitable shelf life for the pharmaceutical product and recommended storage conditions, in order to ensure patient safety.
• the present invention relates to a lyophilized composition
• a lyophilized composition comprising the disodium salt of 5,10-methylene-(6R)-tetrahydrofolic acid (5,10-CH2-(6R)-THF*Na2), citrate and an alkali metal sulfate.
• the present invention relates to stable lyophilizates which contain more than 20 % w/w 5,10-CH2-(6R)-THF*Na2, such as more than 25% w/w, such as more than 30% w/w, such as more than 35% w/w, or such as about 40 % w/w 5,10-CH2-(6R)-THF*Na 2 .
• Lyophilizates of the present invention are substantially amorphous while having an enhanced stability, such as an enhanced storage stability. Lyophilizates of the present invention may by methods known in the art be reconstituted into aqueous pharmaceutical formulations to be administered into a patient in need thereof.
• the present invention in one embodiment discloses a lyophilized composition according to the first aspect wherein the molar ratio of alkali metal sulfate to 5,10-CH2-(6R)-THF*Na2 is from about40 mol-% to about 400 mol-%, preferably from about 50 mol-% to about 100 mol-%.
• the present invention discloses a lyophilized composition according to the first aspect wherein the molar ratio between 5,10-CH2-(6R)-THF*Na2and citrate is from about 200 - 400 mol%, preferably around 350 mol%.
• a second aspect of the present invention is directed to a process for the preparation of the lyophilized composition according to the first aspect, which process comprises the following steps: i. dissolving (6S)-tetrahydrofolic acid in water with NaOH, ii. adjusting the pH of the solution to 8.6 ⁇ 0.5, ill. adding 110-120 mol% formaldehyde, iv. stirring the reaction mixture until reaction has completed, v. adding from about 40 - 200 mol-% of an alkali metal sulfate, and from about 200 - 400 mol-% of citrate, vi. filtering the reaction mixture to obtain a clear solution, and vii. freeze-drying the obtained clear solution, which process does not comprise adding any further reducing agents or antioxidants.
• the alkali metal sulfate added in step v. is in the form of sodium sulfate.
• the citrate added in step v. is in the form of sodium citrate. In another embodiment, the citrate is added as citric acid.
• the present invention further relates to a lyophilized composition comprising 5,10-CH2-(6R)-THF*Na2 according to the first aspect for use in the treatment of cancer, or in cancer therapy, in a human patient.
• the present invention relates to a stable lyophilizate comprising 5,10-CH2-(6R)-THF*Na2 according to the first aspect, or a reconstituted aqueous solution thereof, for use in the treatment of cancer, or in cancer therapy, in a human patient.
• the present invention further relates to a method of treatment of cancer, or of cancer therapy, in human patients comprising administering a lyophilized composition according to the first aspect, to a human patient in need thereof.
• the present invention relates to a method of treatment of cancer in human patients comprising administering a lyophilized composition comprising 5,10-CH2- (6R)-THF*Na2 according to the first aspect, or a reconstituted aqueous solution thereof, to a human patient in need thereof
• the present invention further relates to the use of a lyophilized composition comprising 5,10-CH2-(6R)-THF*Na2 according to the first aspect for the manufacture of a medicament for the treatment of cancer in human patients.
• a further aspect is directed to reconstituted pharmaceutical compositions of the lyophilisates of the present invention comprising 5,10-CH2-(6R)-THF*Na2 and a pharmaceutically acceptable carrier or diluent, such as sterile water or a liquid pharmaceutically acceptable vehicle, optionally further comprising at least one additional therapeutic agent including but not limited to, bactericides, antibiotics, antivirals, antiseptics, antineoplastics, anticancer compounds such as chemotherapeutic agents, antifungals, and/or anti-inflammatory agents or other bioactive or therapeutic agents that are suitable for human use, in particular anticancer compounds such as chemotherapeutic agents, for example 5-FU and derivatives, and antifolates, e.g. methotrexate, Pemetrexed.
• chemotherapeutic agents for example 5-FU and derivatives
• antifolates e.g. methotrexate, Pemetrexed.
• the lyophilizates of the invention are in substantially unsolvated, anhydrous form, which includes compounds that are completely free of water and compounds which may contain traces of water.
• Such possible residual (not stoichiometric) amounts of water may be any amount of water, but typically ranges from 0 wt.-% H2O to 3 wt.-% H2O, preferably between 0 wt.-% H2O to 1 wt.-% H2O, such as between 0.05 wt.-% H2O to 1 wt.-% H2O.
• Example 1 Preparation of an aqueous solution comprising disodium 5,10-methylene-(6R)- tetrahydrofolate, citrate and sodium sulfate
• the so obtained solution of disodium 5,10-methylene-(6R)-tetrahydrofolate may be optionally be purified by the following steps (b) and (c) by precipitation of a sulfate salt of 5,10-CH2-(6R)-THF followed by redissolution with sodium hydroxide.
• step (c) (Optional) The product of step (b) was dissolved in 50 mL 0.1 N NaOH under nitrogen, and the pH was adjusted to 8.6 ⁇ 0.50 with 1.5 N NaOH.
• step (d) 21 gr citric acid in 20 ml water was added to the solution in step (c) or step (a), and adjustment of the sulfate content up to 200 mol% was performed with aqueous sodium sulfate if necessary.
• the total volume was then adjusted to 100 mL with sterile filtered water and filtered using a 0.22 pm filter, preferably a hydrophilic PVDF type e.g. Millipore Durapore® 0.22pm.
• the filtrate was filled into vials (2ml or 160 mg 5,10-CH2-(6R)-THF*Na2 per vial) while keeping the solution as cold as possible.
• Example 2 Preparation of a lyophilized composition comprising disodium 5,10-methylene- (6R)-tetrahydrofolate, citrate and sodium sulfate
• the vials from Example 1 were frozen and subsequently freeze-dried.
• the vials were sealed under a slight vacuum with nitrogen in the headspace, and crimped.
• the resulting lyophilisate contains more than 30% w/w 5,10-CH2-(6R)-THF*Na2.
• Example 3 Stability testing a) Stability of a solution comprising disodium 5,10-methylene-(6R)-tetrahydrofolic acid, citrate and sulfate at at 25°C
• step (d) In order to determine the stability of a sterile filtered solution comprising disodium 5,10- methylene-(6R)-tetrahydrofolic acid, citrate and sulfate at 25°C, a solution as prepared in Example 1, step (d) was stored at 25°C. The purity of 5,10-CH2-(6R)-THF was measured by HPLC at periodic intervals (% area). The results are shown in Figure 4.
• the stability test solution was stored in a refrigerator (2°C to 8°C) during the investigation, and only taken out for analytical sampling. During the sampling no protection from light was used. At 2°C to 8°C the purity shows no significant change and remains stable at 97% over a 7-hour storage period.
• the stability test at 5°C was repeated on a comparative test solution to which was added sodium ascorbate (lmg/mL as antioxidant) and stored at 2°C to 8°C.
• the test solution with sodium ascorbate shows no significant difference compared to the test solution without added sodium ascorbate ( Figure 4 and Figure 5).
• the solutions with and without ascorbate may thus be considered equal with regard to stability.
• a solution of 75 mg/mL 5,10-methylene-(6R)-tetrahydrofolate is clear and remains clear regardless if it is stored at 2-8°C or at RT, i.e. no precipitation occurs.
• the solution is slightly viscous and has an osmolality of app. 710 mOsmol/kg.
• a sterile filtered solution comprising 75 mg/mL disodium 5,10-methylene-(6R)- tetrahydrofolic acid, citrate and sulfate is stable up to 7 hours when stored at 2°C to 8°C, and stable up to 4 hours when stored at room temperature.
• a lyophilized composition comprising disodium 5,10-methylene-(6R)- tetrahydrofolate, citrate and sodium sulfate at 5 °C, 25°C, and 40 °C
• a liophilisate as prepared in Example 2 was stored at 5 °C, 25°C, and 40 °C.
• the purity of 5,10-CH2-(6R)-THF was measured by HPLC at periodic intervals (% area). The results relative to the staring value are shown as relative purity in %w/w in Figure 6.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Dermatology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=81984853

Family Applications (1)

Country Status (9)

Citations (9)

• 2023
  • 2023-06-05 KR KR1020257000562A patent/KR20250022145A/ko active Pending
  • 2023-06-05 CA CA3258734A patent/CA3258734A1/en active Pending
  • 2023-06-05 AU AU2023282347A patent/AU2023282347A1/en active Pending
  • 2023-06-05 EP EP23730517.2A patent/EP4536187A1/en active Pending
  • 2023-06-05 JP JP2024570947A patent/JP2025518274A/ja active Pending
  • 2023-06-05 WO PCT/EP2023/064972 patent/WO2023237484A1/en not_active Ceased
  • 2023-06-05 CN CN202380045351.1A patent/CN119365186A/zh active Pending
  • 2023-06-05 IL IL317395A patent/IL317395A/en unknown
  • 2023-06-05 US US18/872,672 patent/US20250360135A1/en active Pending

Patent Citations (15)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events